Detalles de la búsqueda
1.
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Mod Rheumatol
; 34(2): 272-286, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405710
2.
Anti-TNF treatment corrects IFN-γ-dependent proinflammatory signatures in Blau syndrome patient-derived macrophages.
J Allergy Clin Immunol
; 149(1): 176-188.e7, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34175136
3.
Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis.
Mod Rheumatol
; 33(6): 1171-1175, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36197747
4.
Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
Mod Rheumatol
; 33(6): 1162-1170, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399020
5.
Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation.
J Allergy Clin Immunol
; 148(2): 550-562, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33529688
6.
Clinical practice guidance for childhood-onset systemic lupus erythematosus-secondary publication.
Mod Rheumatol
; 32(2): 239-247, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910196
7.
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
Mod Rheumatol
; 31(1): 226-234, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32552266
8.
Safety and effectiveness of adalimumab in Japanese patients with juvenile idiopathic arthritis: Results from a real-world postmarketing study.
Mod Rheumatol
; 31(2): 421-430, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32340508
9.
Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation.
Ann Rheum Dis
; 79(11): 1492-1499, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32647028
10.
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Rheumatology (Oxford)
; 59(9): 2427-2434, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31951279
11.
Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive study.
Mod Rheumatol
; 30(5): 852-861, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31483178
12.
A low-birth-weight risk assessment scale: development and validation through a questionnaire-based survey.
BMC Health Serv Res
; 19(1): 48, 2019 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30658651
13.
Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
Mod Rheumatol
; 29(2): 314-323, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611761
14.
Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.
Mod Rheumatol
; 29(5): 747-755, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30217117
15.
Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018.
Mod Rheumatol
; 29(1): 41-59, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30126298
16.
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Ann Rheum Dis
; 77(3): 348-354, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191819
17.
Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.
Mod Rheumatol
; 28(1): 101-107, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28448193
18.
Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan.
Mod Rheumatol
; 28(5): 826-831, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29293033
19.
Characteristics and outcome of intractable vasculitis syndrome in children: Nation-wide survey in Japan.
Mod Rheumatol
; 28(4): 697-702, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29219653
20.
Survey of attitudes of non-pediatric rheumatologists among councilors of the Japan College of Rheumatology regarding transitional care.
Mod Rheumatol
; 27(6): 1047-1050, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28165841